New Zealand takes significant step towards national hospital medicines list The Pharma Letter One of the changes has been the addition of rituximab (MabThera, from Roche) to the rheumatology list. Rituximab, a targeted biologic medicine, had already been available as a treatment for some forms of leukemia and lymphoma but only some DHBs were ... |
